Internal medicine

Clinical endpoint

Voriconazole

Population

Surgery

Dermatology

Randomized controlled trial

Aspergillosis

Immunology

Posaconazole

Antifungal

Medicine

Environmental health

The Lancet

Posaconazole was non-inferior to voriconazole for all-cause mortality up until day 42 in participants with invasive aspergillosis. Posaconazole was well tolerated, and participants had fewer treatment-related adverse events than in the voriconazole group. This study supports the use of posaconazole as a first-line treatment for the condition.

Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial